Studies were conducted to verify the kinetics of XO inhibition, which showed that the compounds are mixed‐type inhibitors and that they bind to free XO enzymes with high affinities, which may offer a promising therapeutic prospect for the treatment of hyperuricemia. The gene discussed is XDH; the disease is hyperuricemia.